94 results about "Lung tumor" patented technology

The invention concerns a radiofrequency (RF) ablation catheter (100) comprising: a flexible shaft (110) extending between a distal end and a proximal end: an inflatable balloon (120) mounted on the shaft (110); and an RF conductor element (115), wherein a portion of the flexible shaft (110) is distal to the inflatable balloon (120) and is defined as a distal segment (119) of the shaft (110), and wherein the RF conductor element (115) is located on the distal segment (119) and is adapted to electrically contact and to deliver RF energy to a liquid metal (150).

The invention relates to the technical field of medical image processing, in particular to a lung tumor CT image 3D segmentation method and system based on multi-modal image fusion. The method comprises the following steps: acquiring a lung tumor CT image; determining a first texture feature based on the lung tumor CT image; identifying a lung tumor boundary by using the first texture feature; detecting a nodule protrusion area in the boundary of the lung tumor; obtaining tissue infiltration data from the nodule protrusion area; determining a second texture feature according to the tissue infiltration data; determining a tumor heterogeneity feature according to the first texture feature and the second texture feature; evaluating the potential malignancy degree by utilizing tumor heterogeneity characteristics; and dividing a tumor risk area of the lung tumor CT image based on the potential malignancy degree. According to the invention, accurate heterogeneity identification and risk region division of the lung tumor CT image are realized based on a medical image processing technology, and the accuracy of lung tumor 3D segmentation is improved.

The present application provides a pharmaceutical combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The pharmaceutical combination in the present application shows good anti-lung tumor and anti-liver tumor activities.

The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.

The utility model discloses a lung tumor sampling device, which belongs to the technical field of medical instruments and comprises an extraction tube used for extracting tumor tissue liquid, an input end of the extraction tube is provided with a suction needle head, a piston is connected in the extraction tube in a sliding mode, the upper end of the piston is connected with a push-pull rod, and the push-pull rod is connected with the suction needle head. The tumor tissue solid sampling device comprises an extraction tube and a suction needle head, the extraction tube is used for extracting tumor tissue solid, the sampling piece is used for extracting tumor tissue solid, the sampling piece, the extraction tube and the suction needle head are coaxially arranged, and the sampling piece comprises a connecting rod and a sampling needle connected with the end of the connecting rod. And more comprehensive and deep tumor information can be provided, so that the diagnosis accuracy can be improved.

The invention discloses a lung CT tumor image synthesis method based on an artificial intelligence model, and the method comprises the following steps: A1, position selection: applying a pre-trained UNet to CT scanning, segmenting a rough position and a blood vessel region of a lung, and selecting a proper position for a tumor in a region, which is not intersected with a blood vessel, of the lung; a2, texture generation: generating the texture of the tumor from the random Gaussian noise through a neural network; a3 shape generation: a tumor-like shape is generated by using an ellipsoid, and the diversity is enriched by elastic deformation, so that the shape is more similar to a naturally growing tumor in appearance; and A4, performing post-synthesis treatment, and placing the generated tumor shape and texture on the selected points. According to the method, the lung tumor focus is synthesized by using the artificial intelligence network, so that the cost of manual labeling is reduced, and the problems of complex texture, fuzzy edge and noise and artifacts are solved.

The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.

The invention relates to a lung tumor cell diffusion direction marking method and device and computer equipment. The method comprises the following steps: constructing a lymph and blood vessel framework diagram, and identifying a blood vessel structure and a lymph structure in a lung CT image to be marked by adopting a pre-trained machine learning model; registration is carried out according to the lymph and blood vessel framework diagram, and a registered blood vessel structure and a registered lymph structure are obtained; identifying a tumor in the registered lung CT image, a first position relation between the tumor and a registered vascular structure, a second position relation between the tumor and a registered lymph structure, and a third position relation between the tumor in a lung structure; according to the first position relation, the second position relation and the third position relation, the probability and diffusion direction of vascular diffusion, lymphatic diffusion and direct diffusion of tumor cells in the tumor are calculated and marked. By adopting the method, accurate and efficient diffusion marking can be realized.

The invention relates to a traditional Chinese medicine compound composition for inhibiting lung cancer metastasis and application thereof. The traditional Chinese medicine compound composition is prepared from the following raw material medicines in parts by weight: 40-45 parts of radix ophiopogonis, 4-8 parts of pinellia ternate, 4-8 parts of liquorice, 7-11 parts of ginseng, 4-8 parts of polished round-grained rice, 12-20 parts of Chinese dates and 18-27 parts of paris polyphylla. Compared with the prior art, the traditional Chinese medicine composition has a remarkable inhibiting effect on lung cancer metastasis, can remarkably induce lung cancer cell apoptosis and effectively inhibits proliferation and migration of lung cancer cells; animal experiments show that the traditional Chinese medicine composition not only can effectively reduce the number of mouse lung metastatic tumors, but also remarkably reduces the lung tumor metastasis load. In addition, the traditional Chinese medicine composition also remarkably increases the level of NK cells and CD8 + T cells in peripheral blood.

The invention provides a lung stem cell peptide for treating pulmonary nodule as well as a preparation method and application thereof, and belongs to the technical field of biological pharmacy. The method comprises the following steps: performing induced differentiation on iPSC to obtain lung stem cells; lung stem cells are cultured and centrifuged, supernatant is collected, and a lung stem cell crude solution is obtained; mixing the lung stem cell crude liquid with protease, performing enzymolysis, centrifuging, concentrating, and performing spray drying to obtain the lung stem cell peptide for treating pulmonary nodule. By optimizing the composition of each culture medium, the iPSC is induced and differentiated into the lung stem cells, then the lung stem cell peptide is extracted and separated from the lung stem cells, and the extracted lung stem cell peptide migrates to the lung in a vein reinfusion mode, so that the generation of lung tumor nodules can be effectively inhibited, the number of the lung tumor nodules is greatly reduced, and the lung tumor nodules can be effectively inhibited. Toxic and side effects and adverse reactions are avoided.

The present invention discloses a spontaneous early lung cancer mouse model, a construction method and an application thereof, and belongs to the technical field of animal model construction. The present invention hybridizes mice that conditionally overexpress GNGT1 with Scgb1a1‑Cre tool mice that specifically target the lungs, and the F1 generation contains the spontaneous early lung cancer mouse model. The early lung cancer mouse model of the present invention that specifically overexpresses GNGT1 in the lungs can successfully construct an early lung cancer model in a relatively short period of time, which can greatly accelerate the research progress of scientific researchers, save time and costs, and expand the range of available models for lung tumor research. The spontaneous early lung cancer mouse model provided by the present invention has high repeatability and good controllability, and is an important bridge to promote the progress of lung cancer research and ultimately its clinical transformation.

The invention discloses a double-end endoscope robot for lung tumor nodule minimally invasive surgery, and relates to the technical field of medical instruments. The system comprises a header pipe, a first endoscope robot and a second endoscope robot are arranged in the header pipe, the first endoscope robot is composed of a first semicircular flexible inner pipe, a first mechanical arm and a first surgical head connector, and the second endoscope robot is composed of a second semicircular flexible inner pipe, a second mechanical arm and a second surgical head connector. And the overall outer diameter of the second endoscope robot is the same as the inner diameter of the first semicircular flexible inner tube. According to the double-headed robot, the two semicircular flexible inner tubes are arranged, the semicircular flexible inner tubes on the double-headed robot can be converted into whole round tubes after separation, the whole round tubes are kept stable in respective bronchus, double headed operation can be conducted at the same time, physical conflicts cannot be generated, the needed space is small, the double-headed robot is suitable for lung minimally invasive surgery, and the surgery time can be greatly shortened.

NOxPorfin is an on-demand porphyrin-based photosensitizer, described herein, designed to treat cancer via photodynamic therapy (PDT). A distinct advantage over existing FDA-approved photosensitizers is that NOxPorfin exhibits a suppressed singlet oxygen quantum yield (φΔ = 6%) prior to activation within cancer cells. This property translates to a severely compromised ability to harm healthy tissue. However, in the presence of nitric oxide, a common feature of all tumors, photosensitization increases by 650% (φΔ=45%). In addition, this is accompanied by a 70-fold fluorescence signal enhancement, which we designed to confirm NOxPorfin activation via clinical fluorescence imaging. The efficacy of NOxPorfin was successfully demonstrated in two murine models of cancer. First, we were able to selectively ablate aggressive breast cancer cells without causing collateral damage. Second, we were able to prevent the growth of nascent, non-small cell lung tumors. The latter study has implications in treating metastatic lesions.

Two major treatment strategies employed in fighting non-small cell lung cancer (NSCLC) are tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). The choice of strategy is based on heterogeneous biomarkers expressed by the lung tumor tissue. A major challenge for molecular testing of these biomarkers is the insufficiency of biopsy specimens from patients with advanced NSCLC. Disclosed herein is a method for predicting a response to immune-checkpoint blockade immunotherapy. The method generally involves imaging the subject with positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose integrated with computed tomography to produce 18F-FDG PET / CT images of the tumor, analyzing the images using PET, CT, and Kulbek Leibler Divergence statistical (KLD) features or, alternatively using deep leaning such as Neural Networks; generating a radiomic signature from the identified features or Network characteristics; and computing a radiomic score based on the radiomic signature that is predictive of responsiveness to ICIs or TKIs.

Lung cancer remains the leading cause of cancer-related deaths in the world. Despite the fact that introduction of immune checkpoint inhibitors (ICIs) led to a major advancement in lung cancer treatment, disease prognosis continues to remain low and a significant proportion of patients do not respond to such therapies. Cancer vaccines could potentially provide a complementary approach to boost antitumor immunity and act synergistically with ICIs. Novel tumor antigens shared by a large proportion of lung tumor cells are described herein. Several of the tumor antigens described herein derive from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of lung cancer is also described.

The invention discloses application of NCCRP1 as a lung adenocarcinoma immunotherapy biomarker, and belongs to the field of biological medicine. Bioinformatics analysis finds that the NCCRP1 is remarkably and highly expressed in lung adenocarcinoma tissues, and the expression level of the NCCRP1 is in negative correlation with prognosis of a patient. Secondly, the expression level of lung adenocarcinoma cells NCCRP1 is in negative correlation with infiltration of anti-tumor immune cells such as CD8 + T cells. Experiments show that the knockout of the NCCRP1 can significantly inhibit the growth of mouse lung tumors by increasing the infiltration quantity of CD8 + T cells and NK cells in a lung adenocarcinoma microenvironment. The invention provides a new target spot for immunotherapy of lung adenocarcinoma, including NCCRP1 gene editing (knockout / knockdown) and application of an inhibitor in preparation of antitumor drugs.

A method to treat a human patient including: advancing a catheter through a natural airway of the patient and positioning a distal portion of the catheter in the natural airway of a lung of the patient to a target region in the lung, injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight / volume from the distal portion of the catheter into the target region; delivering energy from the distal portion into the conductive hypertonic saline solution in the target region, wherein the energy heats the liquid in the portion of the airway, and ablating the target region with the heated liquid.

This invention belongs to the field of tumor immunotherapy and provides the application of Hdac3 gene knockout formulations or Ikkα gene knockout formulations in the preparation of drugs that inhibit tumor metastasis. The research results of this invention show that Hdac3 and Ikkα gene mutations significantly inhibit lung tumor metastasis and prolong the survival of mice, and this metastasis inhibition is independent of T, B, and NK cells. Simultaneously, this invention also discovers that Hdac3 and Ikkα mutations inhibit lung tumor metastasis by affecting the sensitivity of tumor cells to tumor necrosis factor, making tumor cells more susceptible to apoptosis, thereby providing a method for sustained in vivo killing of tumor cells. This invention also provides a mutant vector, which exhibits good anti-tumor metastasis effects.

The present invention relates to a treatment of cancer. Here, the inventors discovered that flavin-containing monooxygenase 4 (FM04) expression was increased in lung tumor samples compared with lung healthy tissue. They found that this phenotype was a common feature in lung adenocarcinoma promoted also by translocation of EML4 / ALK as well as by oncogenic KRAS or EGFR using dedicated mouse models. Moreover, FMO4 was strongly increased in human lung tumors compared with healthy lung tissue, and FMO4 expression was inversely correlated with overall survival in patients with lung adenocarcinoma. Importantly, FMO4 protected lung cancer cells against reactive oxidative species-induced apoptosis. Finally, FMO4 loss of function decreased oncogenic KRAS-induced human bronchoalveolar cells transformation in vitro and in vivo. Thus, the present invention relates to an FMO inhibitor for use in the treatment of cancer in a subject in need thereof.

The invention discloses an auxiliary lung cancer examination tool based on biological tissue fibrous structure morphological analysis, which is characterized in that the morphological condition of a biological tissue fibrous structure in an extracellular matrix is analyzed through multi-photon microscopic imaging, and an auxiliary lung cancer examination model is established; morphological multivariate parameter quantitative characterization is performed on an elastic fiber image and a collagenous fiber image, and then the similarity degree of the two fibers on multiple morphological characteristics is comprehensively characterized on the basis, so that a normalized similarity index map is generated. According to the method, the distribution information of the elastic fibers and the collagenous fibers in the lung tissue extracellular matrix can be rapidly extracted, the lung tumor evolution level is judged according to the difference of morphological distribution similarity conditions of the two fibrous structures of a normal person and a lung cancer patient, and the method serves as a novel examination method provided by the invention. The method has great clinical transformation potential, can more accurately analyze the morphological condition of the fibrous structure of the biological tissue, and has greater application potential compared with the traditional method.

The invention provides an A type 12, 13-epoxy trichothecene compound or a pharmaceutically acceptable salt thereof, and a compound with a chemical formula (I), and the compound has growth inhibition activity on A549, NCI-H1650, NCI-H1944 lung cancer cells and BEAS-2B normal lung cells, and can provide a lead compound for developing lung tumor treatment drugs.

The present disclosure relates to the determination of lung cancer using miRNA ratios. The present invention provides methods of determining the presence of a lung tumor in a subject. Also provided are methods of determining the presence of an invasive lung tumor in a subject. In addition, methods of determining the risk of developing a lung tumor in a subject are provided. Also provided are methods of determining the risk of developing an invasive lung tumor in a subject. Also provided are methods of predicting the risk of developing or having a lung tumor in a subject. Also provided are methods of establishing lung cancer treatment options.

The invention discloses a novel application of ginkgo biflavone in lung cancer treatment, belongs to the technical field of medicines, and researches show that ginkgo biflavone can target CDC7 and is a novel targeted medicine. It is confirmed for the first time that ginkgo biflavone regulates and controls the thermal stability and enzymatic degradation of ginkgo biflavone through targeting CDC7 kinase (binding free energies-8.3 kcal / mol), directly intervenes in the DNA replication process, and provides a natural drug lead compound for development of a novel CDC7 small-molecule inhibitor. The compound has great significance in preventing and treating malignant tumors, and has a wide prospect in the aspect of preparing medicines for treating lung tumors.

The invention provides a real-time 4D-CBCT imaging method based on a Unet-Transform model, and the method comprises the steps: constructing a comprehensive cascade deep learning network model integrating a Unet network and a Transform network, training the network model, inputting a plurality of CBCT projections containing different respiratory movement amplitudes, which are collected at the same rack angle at the online treatment moment of a patient, into the trained network model, the model outputs three PCA feature tags of a DVF between a predicted phase of breathing motion of a patient at the current moment and a reference phase corresponding to CBCT projection in real time, the PCA feature tags are converted into the DVF through principal component analysis, a reference phase image of an earlier-stage 4D-CT of the patient is deformed under the guidance of the DVF, a corresponding 4D-CBCT image of the breathing phase at the current moment is obtained, and the CBCT image of the breathing motion of the patient at the current moment is obtained. And finally, a 4D-CBCT image sequence capable of covering a complete respiratory cycle is obtained. According to the method, dynamic volume imaging is carried out on the patient during SBRT fractional treatment beam exiting by utilizing a Unt-Transform network model framework, a tool for accurately monitoring movement of tumors in the lung during beam exiting treatment of the patient is provided for clinicians, and technical guarantee is provided for accurate and safe implementation of the lung cancer SBRT.

The medical optical tracking system of the present invention includes a light source and an optical tracking carrier. The optical tracking carrier includes a light-guiding material such as a light-emitting optical fiber. The light emitted from the light source is transmitted through the optical tracking carrier and then optically tracked on the optical tracking carrier. The light source adopts a medical cold light source, and may adopt an LED light source, in particular, the light-emitting end of the mini-sized LED light source can be directly integrated with the optical tracking carrier and set in the human body to perform optical tracking. The medical optical tracking system of the present invention can be manufactured as a visible light tracking medical catheter, a visible light tracking solid tumor tracking device, a visible light tracking optical fiber, or a visible light tracking blood vessel tracking device as required, which is used in clinical surgery to track the internal cavity of blood vessels, esophagus, ureter, urethra, etc., or to track and define the position of solid tumors such as uterine fibroids, lung tumors, liver tumors, etc., thereby improving the accuracy of surgery and avoiding accidental damage during surgery.

This invention relates to the field of pharmaceutical technology, specifically proposing the application of ligustilide in the preparation of drugs for inhibiting and / or preventing and / or alleviating and / or treating lung tumors to address the current lack of natural drugs for lung cancer prevention. Lung tumors are nitrosamine-induced carcinogenesis of lung tissue. The invention relates to a pharmaceutical preparation for inhibiting and / or preventing and / or alleviating and / or treating lung tumors, comprising an active ingredient and pharmaceutically acceptable excipients; wherein the active ingredient is ligustilide. Ligustilide directly targets the STING protein, activates the cGAS-STING pathway, promotes STING phosphorylation and cell-mediated immune surveillance, while simultaneously regulating ROS homeostasis and the inflammatory microenvironment, reducing nitrosamine damage to lung epithelial cells, and preventing nitrosamine-induced lung carcinogenesis.

This utility model discloses a voice tremor nursing teaching model in the field of nursing teaching aids. It includes a three-dimensional humanoid model with a left lung model and a right lung model positioned at the chest area. The left lung model is covered with a silicone membrane, forming a pleural cavity model. A catheter is located at the top of the left lung model, with one end extending into the pleural cavity model. Air or liquid is injected into the pleural cavity through the catheter to simulate pneumothorax or pleural effusion. The right lung model includes a detachable and replaceable lung cavity model, lung tumor model, and bronchial obstruction model. A bronchial model is located between the left and right lung models, with a microphone connected to the top of the bronchial model. The two forked ends of the bronchial model at the bottom are connected to the left and right lung models, respectively. This device can replace different models to simulate pathological states, allowing students to intuitively experience the differences in voice tremor under different pathological conditions, improving teaching effectiveness and students' clinical skills training level.

The present invention discloses a dual-targeting molecule based on hyaluronic acid and glucose, a preparation method and application thereof, in particular, a dual-targeting fluorescent probe and anti-tumor drug based on hyaluronic acid and glucose. The dual-targeting fluorescent probe utilizes the interaction between HA-CD44 and Glc-GLUT1 to simultaneously target the CD44 and GLUT1 receptors of tumors (e.g., lung tumors), and can deliver fluorescent molecules into tumor cells in a targeted manner, reducing the aggregation of fluorescent molecules in normal cells; at the same time, the tumor cell endocytosis efficiency of fluorescent molecules can be improved. The chemical structures of the two targeting molecules HA and glucose in the dual-targeting fluorescent probe are clear, and the covalent bond connection sites and compositions are clear. This feature provides dual-targeting molecules with very good research and application value in drug delivery system applications and innovative drug development.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to medicinal ink for accelerating lung tumor cell apoptosis and a preparation method and application thereof. Different raw materials are subjected to esterification modification, fermentation or enzymolysis, so that the fat solubility and cell membrane permeability of the composition are promoted, active ingredients can penetrate through a qi and blood barrier more easily to enter lung tissues, the action time is prolonged, the targeting property of the composition is improved, and the conversion of chemical components of traditional Chinese medicines is promoted; a new substance with higher anti-cancer activity is generated or obtained; the bioavailability of each raw material is improved, and a specific enzymolysis product is generated, so that the apoptosis of tumor cells is accelerated. Therefore, different raw materials are specifically prepared, release of active functions of the raw materials is guaranteed from multiple dimensions, and lung tumor cell apoptosis is remarkably accelerated.

The invention is a model of research and methodology to explore the treatment options for a particular case of lung cancer as an adjuvant therapy after surgical removal of a lung tumor. In practice, the excised / removed tumor is usually examined in the pathology laboratory for revision of the diagnosis, but no functional testing is performed for its sensitivity to subsequent adjuvant 5 therapy. In addition, the tumor is disposed of as unnecessary waste. Our proposal is that the tumor remains should be harvested for cellular studies and, using the model and methodology developed and described herein, preliminary answers can be obtained within 2-3 weeks, predicting which chemotherapeutic agents are likely to have a stronger effect and which therapy is likely to be ineffective for an individual lung cancer patient.